1. Clinical Overview
Solifenacin succinate is a competitive, specific muscarinic acetylcholine receptor antagonist (antimuscarinic) used for the treatment of overactive bladder (OAB) syndrome with symptoms of urge urinary incontinence, urgency, and urinary frequency. It exhibits functional selectivity for the M3 receptor subtype, which is the primary mediator of detrusor muscle contraction in the human bladder. It is a once-daily oral medication.
| Onset | Duration | Bioavailability |
|---|---|---|
| Clinical improvement in symptoms may be observed within 1-2 weeks of starting therapy, with maximal therapeutic effect typically achieved by 4-12 weeks. | Approximately 24 hours, supporting once-daily dosing. | Approximately 90%. |
2. Mechanism of Action
Solifenacin is a competitive antagonist of muscarinic acetylcholine receptors. In the bladder, acetylcholine released from parasympathetic nerves activates primarily M3 receptors on detrusor smooth muscle, leading to contraction. By blocking these receptors, solifenacin inhibits involuntary detrusor contractions, increases bladder capacity, reduces the frequency of micturition, and diminishes urgency.
3. Indications & Uses
- Overactive Bladder (OAB) with symptoms of urge urinary incontinence
- Overactive Bladder with symptoms of urgency
- Overactive Bladder with symptoms of increased urinary frequency
4. Dosage & Administration
Adult Dosage: The recommended dose is 5 mg once daily. If well tolerated but requires greater efficacy, the dose may be increased to 10 mg once daily. The 10 mg dose should not be exceeded.
Administration: To be taken orally with a full glass of water, with or without food. The tablet should be swallowed whole, not chewed, crushed, or split. It is recommended to take it at approximately the same time each day.
5. Side Effects
Common side effects may include:
- Dry mouth (10-27%)
- Constipation (5-13%)
- Blurred vision (3-5%)
- Dyspepsia
- Nausea
- Dry eyes
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Ketoconazole, Itraconazole, Voriconazole, Posaconazole | Potent CYP3A4 inhibitors increase solifenacin plasma concentrations. Risk of toxicity. | Major |
| Clarithromycin, Telithromycin, Erythromycin | Potent CYP3A4 inhibitors increase solifenacin plasma concentrations. | Major |
| Ritonavir, Nelfinavir, other strong CYP3A4 inhibitors | Increase solifenacin plasma concentrations. Dose of solifenacin should not exceed 5 mg. | Major |
| Other anticholinergic agents (e.g., oxybutynin, tolterodine, tricyclic antidepressants, first-gen antihistamines, phenothiazines) | Additive anticholinergic effects (dry mouth, constipation, blurred vision, urinary retention, confusion). | Moderate |
| Drugs that prolong QT interval (e.g., Class Ia/III antiarrhythmics, macrolides, some antipsychotics, some fluoroquinolones) | Theoretical additive risk of QT prolongation. Use with caution. | Moderate |
| Cholinergic agonists (e.g., bethanechol) | Solifenacin may antagonize the effects of these drugs. | Moderate |
| Metformin | Solifenacin may slightly decrease the absorption rate of metformin, but clinical significance is likely minimal. | Minor |
7. Patient Counselling
- DO take the tablet exactly as prescribed, once daily.
- DO swallow the tablet whole with water; do not crush or chew.
- DO inform your doctor if you have liver, kidney, heart, or stomach/intestinal problems.
- DO inform your doctor of all other medicines, vitamins, and herbal supplements you are taking.
- DONT consume grapefruit or grapefruit juice while on this medication.
- DONT take a double dose to make up for a missed one. Skip it and take the next dose at the regular time.
- DONT stop the medication abruptly without consulting your doctor, even if you feel better.
8. Toxicology & Storage
Overdose: Symptoms are primarily related to exaggerated anticholinergic effects: severe dry mouth, severe constipation, urinary retention, blurred vision, tachycardia, drowsiness, agitation, hallucinations, and QT prolongation. In severe cases: respiratory depression, convulsions, delirium, cardiac arrhythmias.
Storage: Store at room temperature (15°C to 30°C), protected from light and moisture. Keep out of reach of children. Do not use after the expiry date printed on the pack.